{"prompt": "['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 28 of 169', 'Panel 5 Schedule of trial procedures: short-term extension and follow-up (selected countries)', 'Open-label short-term extension\u00b9', 'FU2\u00b3', 'Visit', '31', '32', '33', '34', '35', '36', '37', '38\u00b2', '39', 'Week', '54', '56', '58', '60', '62', '64', '66', '68', '82', 'Visit window (days)', '+3', '+3', '+3', '+3', '+3', '3', '+3', '+3', '3', 'Trial products (Section 9)', 'IMP administration and compliance', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Concomitant medications/procedures', 'X4', 'X', 'X4', 'X', 'X4', 'X', 'X4', 'X', 'X', 'Investigator assessments of efficacy (Section 10.3.1)', 'IGA', 'X', 'X', 'X', 'X', 'EASI', 'X', 'X', 'X', 'X', 'SCORAD', 'X', 'X', 'X', 'X', 'Safety assessments (Sections 10.4 and 11)', 'Vital signs', 'X4', 'X', 'X4', 'X', 'X4', 'X', 'X4', 'X', 'X', 'Physical examination', 'X', 'X', 'ECG', 'X', 'X', 'X', 'Urine pregnancy test', 'X', 'X', 'X', 'X', 'X', 'Serum chemistry, haematology, and IgE', 'X', 'X', 'X', 'X', 'X', 'Urinalysis', 'X', 'X', 'X', 'X', 'Pharmacokinetics', 'X', 'X', 'ADA', 'X', 'X', 'Adverse events', 'X4', 'X', 'X4', 'X', 'X4', 'X', 'X4', 'X', 'X', 'eDoc-00631888 - Version 4.0']['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 29 of 169', '1) Only subjects who join the open-label tralokinumab arm at Week 16.', '2) Assessments to be done at an early termination visit.', '3) All subjects will have a safety follow-up (FU2) 16 weeks after last administration of IMP. This is considered the end of trial visit.', '4) Not applicable for subjects self-administering tralokinumab (home-use; selected countries only; Sections 7.1 and 9.2).', \"ADA, anti-drug antibodies; EASI, Eczema Area and Severity Index; ECG, electrocardiogram; IGA, Investigator's Global Assessment; IgE, immunoglobulin E;\", 'IMP, investigational medicinal product; SCORAD, Scoring Atopic Dermatitis.', 'eDoc-00631888 - Version 4.0']['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 30 of 169', '5 Introduction and rationale', '5.1 Atopic dermatitis', 'Atopic dermatitis (AD) is a chronic inflammatory skin disease that may affect up to 20% of', 'children and up to 10% of adults. In its severe form, AD is characterised by widespread skin', 'lesions, intractable itch, as well as enhanced susceptibility to bacterial, viral, and fungal skin', 'infections (1-4). AD is associated with a substantial patient burden that typically includes poor', 'quality of life, sleep disturbance, and reductions in work productivity (5).', 'Treatment recommendations for AD include topical therapies, the main being topical', 'corticosteroids (TCS). Unfortunately, TCS and topical calcineurin inhibitors (TCIs) have', 'limited efficacy in patients with moderate-to-severe disease. TCS and non-biologic systemic', 'therapies are all associated with toxicities with long-term use (6-8).', 'AD is characterised by an activated T-helper-2 (Th2) pathway with increased skin expression', 'of key Th2 cytokines including interleukin (IL)-13 (9, 10). The expression of IL-13 is', 'increased in lesional skin compared to non-lesional skin, and the proportion of CD44 and', 'CD84 cells expressing IL-13 is upregulated in AD patients compared to individuals without', 'AD (9, 11).', 'IL-13 acts on keratinocytes to release C-C motif chemokine 22 (CCL22) and recruit more', 'IL-13 expressing Th2 cells, decrease differentiation, and contribute to decreased barrier', 'function (12). IL-13 also drives immunoglobulin E (IgE) production and contributes to mast', 'cell activation status and, once allergen cross-links IgE on the cell surface, drives histamine', 'release and induces itch (13, 14). Indeed, itch is a key issue in AD, which drives significant', 'mechanical damage to the skin and further facilitates allergen and pathogen entry.', 'All of these effects together drive and exacerbate the disease phenotype. A review of the', 'available preclinical literature from mouse and human ex vivo models suggests IL-13 as a, if', 'not the, central mediator of the AD skin phenotype. Indeed, there is evidence that blocking the', 'IL-4 receptor (which is part of the receptor complex which also binds IL-13) with the', 'monoclonal antibody dupilumab leads to clinical improvement in AD subjects (15).', '5.2 Experience with investigational medicinal product', 'Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that', 'specifically binds to human IL-13 and blocks interaction with the IL-13 receptors (16-18). A', 'compilation of clinical and nonclinical data on tralokinumab including pharmacokinetics (PK)', \"is given in the current Investigator's Brochure.\", 'eDoc-00631888 - Version 4.0']\n\n###\n\n", "completion": "END"}